Peptide receptor radionuclide therapy (PRRT) special issue.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.70014
- By:
- Publication type:
- Article
Works matching IS 09538194 AND DT 2025 AND VI 37 AND IP 3
Results: 15
1
2
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.70013
- By:
- Publication type:
- Article
3
Frontiers in radiopharmaceuticals for neuroendocrine tumors.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.70006
- By:
- Publication type:
- Article
4
Synthesis and characterisation of DOTA‐kisspeptin‐10 as a potential gallium‐68/lutetium‐177 pan‐tumour radiopharmaceutical.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13487
- By:
- Publication type:
- Article
5
The role of combined FDG and SST PET/CT in neuroendocrine tumors.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13474
- By:
- Publication type:
- Article
6
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13469
- By:
- Publication type:
- Article
7
Toxicity manifestations encountered in peptide receptor radionuclide therapy setting.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13464
- By:
- Publication type:
- Article
8
Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13463
- By:
- Publication type:
- Article
9
Developing a peripheral blood RNA‐seq based NETseq ensemble classifier: A potential novel tool for non‐invasive detection and treatment response assessment in neuroendocrine tumor patients receiving <sup>177</sup>Lu‐DOTATATE PRRT.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13462
- By:
- Publication type:
- Article
10
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13461
- By:
- Publication type:
- Article
11
PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC).
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13443
- By:
- Publication type:
- Article
12
Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13425
- By:
- Publication type:
- Article
13
Issue Information.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/bju.16761
- Publication type:
- Article
14
Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13379
- By:
- Publication type:
- Article
15
Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
- Published in:
- Journal of Neuroendocrinology, 2025, v. 37, n. 3, p. 1, doi. 10.1111/jne.13355
- By:
- Publication type:
- Article